NVP-BYL719

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2014

2014

NVP-BYL719, a novel PI3K-alpha selective inhibitor, overcomes acquired erlotinib resistance via upregulation of the PI3K/Akt/ mTOR pathway in pancreatic ductal adenocarcinoma

Matthew H F WongA. Xue Ross C. Smith
2014
Corpus ID: 79885407

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with few treatment options. Epidermal growth factor receptor…